ストックスクリーナーアプリを入手
12.94
6.50%
0.79
プレマーケット:
12.85
-0.09
-0.70%
前日終値:
$12.15
開ける：
$12.3
24時間の取引高:
680.85K
Relative Volume:
0.73
時価総額：
$537.27M
収益：
-
当期純損益:
$-2.45B
株価収益率:
-0.0339
EPS:
-381.9068
ネットキャッシュフロー:
$-144.67M
1週間 パフォーマンス:
-0.46%
1か月 パフォーマンス:
-19.43%
6か月 パフォーマンス:
-61.73%
1年 パフォーマンス:
-23.64%
1日の値動き範囲:
$12.30
$13.17
1週間の範囲:
$11.70
$13.78
52週間の値動き範囲:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Compare VOR vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
12.94 | 537.27M | 0 | -2.45B | -144.67M | -381.91 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-19 | 開始されました | Wells Fargo | Overweight |
| 2026-01-09 | 開始されました | Citigroup | Buy |
| 2025-12-17 | 開始されました | TD Cowen | Buy |
| 2025-12-09 | 開始されました | JP Morgan | Overweight |
| 2025-11-25 | 再開されました | Wedbush | Neutral |
| 2025-10-15 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | アップグレード | Stifel | Hold → Buy |
| 2025-06-30 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | 開始されました | Wedbush | Outperform |
| 2022-04-27 | 開始されました | Goldman | Neutral |
| 2021-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2021-12-03 | 開始されました | Robert W. Baird | Outperform |
| 2021-12-02 | 開始されました | Oppenheimer | Outperform |
| 2021-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-03-25 | 開始されました | B. Riley Securities | Buy |
| 2021-03-03 | 開始されました | Barclays | Overweight |
| 2021-03-03 | 開始されました | Evercore ISI | Outperform |
| 2021-03-02 | 開始されました | Goldman | Sell |
| 2021-03-02 | 開始されました | Stifel | Buy |
すべてを表示
Vor Biopharma Inc (VOR) 最新ニュース
Profit Recap: What are analysts price targets for Vor Biopharma IncQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Vor Bio reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vor Biopharma Inc.(NasdaqGS: VOR) added to S&P Biotechnology Select Industry Index - marketscreener.com
If You Invested $1,000 in Vor Biopharma Inc. (VOR) - Stock Titan
Short Covering: Should value investors consider Vor Biopharma Inc2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Vor Biopharma Inc - GuruFocus
Wells Fargo initiates coverage of Vor Biopharma (VOR) with overweight recommendation - MSN
Wells Fargo Initiates Coverage on VOR with Overweight Rating | V - GuruFocus
Vor Biopharma (NASDAQ:VOR) Now Covered by Wells Fargo & Company - MarketBeat
Wells Fargo Initiates Vor Biopharma at Overweight With $30 Price Target - marketscreener.com
H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target - MSN
RA Capital raises Vor Biopharma (VOR) reported beneficial stake to 19.9% - Stock Titan
Vor Biopharma Inc expected to post a loss of $1.64 a shareEarnings Preview - TradingView
Fcpm Iii Services B.V. Takes $18.50 Million Position in Vor Biopharma Inc. $VOR - MarketBeat
Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
About Us | Oil & Gas JournalVor Biopharma Inc.Common Stock (Nasdaq:VOR) Stock Quote - FinancialContent
Guidance Update: Can Vor Biopharma Inc keep up with sector leadersTrade Exit Report & Reliable Breakout Forecasts - baoquankhu1.vn
Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Up 24.5% in February - MarketBeat
VOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VOR: Telitacicept advances in late-stage trials for MG and Sjögren's, targeting major autoimmune markets - TradingView
VOR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference - GlobeNewswire
Pharma News: What are the analyst revisions for Vor Biopharma IncIs DMAC stock a good investment in YEARJuly 2025 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Vor Biopharma Inc (VOR) Stock Price, Quote, News & History - Benzinga
[SCHEDULE 13G/A] Vor Biopharma Inc. Amended Passive Investment Disclosure - Stock Titan
Vor Bio Names Khan as Chief Medical Affairs Officer - Intellectia AI
Vor Bio Announces Inducement Grants in Compliance with Nasdaq Listing Rule 5635(c)(4) - Intellectia AI
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
VOR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VOR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Qiming funds disclose Vor Biopharma (VOR) common-stock holdings below 5% - Stock Titan
Vor Biopharma (NASDAQ:VOR) Stock Price Down 4%What's Next? - MarketBeat
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
Exit Recap: Can Vor Biopharma Inc. keep up with sector leadersJuly 2025 Opening Moves & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
VOR Stock Unaffected by Selling Stockholders' Actions - GuruFocus
Is Vor Biopharma Inc. gaining market shareDollar Strength & Real-Time Stock Price Movement Reports - mfd.ru
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug EndMonth: What is the PEG ratio of Vor Biopharma IncGap Down & High Conviction Trade Alerts - baoquankhu1.vn
Vor Biopharma Inc. (VOR) Presents at 44th Annual J.P. Morgan Healthcare ConferenceSlideshow - Seeking Alpha
VOR: TD Cowen Initiates Coverage with a 'Buy' Rating | VOR Stock News - GuruFocus
VOR: Telitacicept drives a global autoimmune strategy, backed by strong data, funding, and expert leadership - TradingView — Track All Markets
Form 8K Vor Biopharma Inc For: 12 January By Investing.com - Investing.com
Quarterly Risk: How Vor Biopharma Inc stock valuations compare to rivals2025 Retail Activity & Weekly Top Performers Watchlists - Bộ Nội Vụ
Vor Biopharma Inc. Common Stock (VOR) Stock Price Today & Analysis - Gotrade
Citigroup Initiates Coverage of Vor Biopharma (VOR) with Buy Recommendation - Nasdaq
Vor Biopharma (VOR) Receives New 'Buy' Rating From Citigroup | V - GuruFocus
Citigroup Begins Coverage on Vor Biopharma (NASDAQ:VOR) - MarketBeat
Citi Starts Vor Biopharma, Inc. (VOR) at Buy - StreetInsider
How Vor Biopharma Inc. stock responds to policy changes2025 EndofYear Setup & Growth Focused Investment Plans - ulpravda.ru
Vor Biopharma Inc (VOR) 財務データ
収益
当期純利益
現金流量
EPS
Vor Biopharma Inc (VOR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 28 '25 |
Sale |
27.42 |
124,311 |
3,408,230 |
1,055,749 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 30 '25 |
Sale |
25.12 |
24,579 |
617,424 |
779,652 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 27 '25 |
Sale |
28.12 |
90,941 |
2,557,261 |
1,180,060 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 23 '25 |
Sale |
28.01 |
76,880 |
2,153,409 |
1,324,346 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 24 '25 |
Sale |
28.01 |
53,345 |
1,494,193 |
1,271,001 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 20 '25 |
Sale |
29.67 |
92,023 |
2,730,483 |
0 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 21 '25 |
Sale |
28.11 |
25,027 |
703,509 |
1,401,226 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 17 '25 |
Sale |
30.25 |
25,717 |
777,987 |
1,178,725 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 20 '25 |
Sale |
30.05 |
11,616 |
349,101 |
1,167,109 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 21 '25 |
Sale |
30.07 |
200 |
6,015 |
1,166,909 |
1.82%
大文字化:
|
ボリューム (24 時間):